- Brief Report
- Open Access
Intravitreal bevacizumab as an adjunct to vitrectomy in advanced Eales’ disease
© The Author(s) 2011
- Received: 3 October 2011
- Accepted: 4 November 2011
- Published: 17 November 2011
This study aimed to report the use of intravitreal bevacizumab as an adjunctive treatment in two cases of advanced Eales’ disease with vitreous haemorrhage and tractional retinal detachment, prior to vitreoretinal surgery.
In two patients presenting with vitreous haemorrhage, retinal neovascularisation and localised tractional retinal detachment, 1.25 mg of intravitreal bevacizumab was injected prior to vitrectomy, membrane peeling and endolaser photocoagulation of retina.
Regression of the retinal neovascularisation with resolution of dye leakage on fluoroscein angiography was observed in both cases. Membrane peeling could be performed with minimal bleeding during vitreoretinal surgery in both cases.
Bevacizumab may be a possible adjunctive treatment to vitreoretinal surgery for the management of Eales’ disease with tractional retinal detachment.
- Eales’ disease
- Tractional retinal detachment
Eales’ disease although occurring worldwide is encountered commonly in the Indian subcontinent. It affects healthy young adults aged 20–30 years with a male preponderance . The characteristic clinical features include occlusive peripheral retinal vasculitis leading to capillary non-perfusion and ischemia followed by neovascularisation of the disc and retina and subsequently recurrent vitreous haemorrage and tractional retinal detachment. Photocoagulation is the mainstay of therapy in the proliferative stage of Eales’ disease .
Recently, intravitreal bevacizumab has been explored as a possible therapeutic modality in the management of early stages of Eales’ disease [2–5]. We report two cases of Eales’ disease with tractional retinal detachment where bevacizumab was used intravitreally as an adjunctive treatment prior to vitreoretinal surgery. To our knowledge, this is probably the first report where adjunctive bevacizumab used preoperatively in a relatively advanced stage of the disease facilitated the removal of fibrovascular membranes with minimal intra- and post-operative complications.
Six weeks post-injection, vitreoretinal surgery was performed with membrane peeling and endolaser photocoagulation. Membrane peeling was easily performed without the need of diathermy during surgery. On the first post-operative day, adequate fundal glow indicated proper haemostasis without post-operative oozing. At 2 weeks follow-up, BCVA in the right eye improved to 6/36 (Snellen chart). On fundus evaluation, there was absence of retinal or disc neovascularisation. Fluorescein angiogram (Fig. 1c, d) revealed absence of leakage from regressed vessels and an appropriately lasered peripheral retina. Staining of the inferotemporal vessel seen in the late phase indicated healed vasculitis. At 6 months follow-up, BCVA was maintained without recurrence of neovascularisation or vitreous haemorrhage.
Four days post-injection, fundus evaluation and fluorescein angiogram revealed mild regression of new vessels and persistence of the dye leakage. Twenty days later, repeat FA showed staining of fibroglial tissue without any leakage of dye from the regressed vessels (Fig. 2c, d). On 21st day post-injection, a three-port pars plana vitrectomy was performed along with membrane peeling followed by endolaser photocoagulation and silicone oil tamponade. There was minimal bleeding during membrane peeling. Post-operatively, the patient was prescribed with ofloxacin drops four times a day and prone positioning was advised. On the first post-operative day, there was adequate fundal glow and the retina appeared settled with silicone oil in situ and endolaser marks could be visualised. Four weeks later, BCVA improved to 6/60.
It is well established that retinal ischaemia stimulates the production of vascular endothelial growth factor (VEGF), a key mediator of angiogenesis. Massive expression of VEGF in the neovascular membranes in Eales’ disease has also been reported previously [6, 7]. Bevacizumab, a humanised monoclonal antibody against VEGF, is currently emerging as an effective off-label treatment for a variety of ocular disorders such as neovascular age-related macular degeneration, macular edema secondary to central retinal vein occlusion and proliferative diabetic retinopathy . However, a literature search revealed only few anecdotal reports on the use of intravitreal bevacizumab in Eales’ disease [2–5]. In all the reports, bevacizumab had been used in early stages of the disease without retinal detachment. In contrast, our cases had fairly advanced Eales’ disease with tractional retinal detachment, and bevacizumab was effective in promoting regression of neovascularisation, thus facilitating membrane dissection by reducing intra-operative bleeding. Additionally, due to better visibility during surgery, the chances of causing iatrogenic retinal breaks were also reduced. Although photocoagulation is the preferred modality of treatment in the proliferative stage of Eales’ disease, it could not be performed in both our cases due to the presence of dispersed vitreous haemorrhage and tractional retinal detachment. Nevertheless, there was no recurrence of neovascularisation at 6 months follow-up in our first patient, and at the time of writing this report, the second patient had been followed up for 2 months without recurrence of neovascularisation.
In both our cases, sequential treatment with bevacizumab followed by vitrectomy was beneficial and associated with fair visual outcome, despite the presence of tractional retinal detachment. However, the appropriate time interval between bevacizumab injection and vitreoretinal surgery in the presence of tractional retinal detachment is not established. The minimum concentration (500 ng/ml) of intravitreal bevacizumab (1.25 mg) that completely inhibits VEGF-A-induced endothelial cell proliferation is reportedly maintained for 6–7 weeks, after which repeat administration of bevacizumab may be required . We performed vitreoretinal surgery within 3–6 weeks after injection of bevacizumab as the anti-angiogenic effect of drug was expected to be maintained during this period while allowing reasonably sufficient time for regression of neovascularisation. Additionally, in our first case, non-recurrence of neovascularisation at 6 months follow-up suggests that intermediate-term control is achievable with intravitreal bevacizumab and vitreoretinal surgery, even with a background of ongoing ischemic disease. Although recent studies have strengthened the favourable short-term safety profile of intravitreal bevacizumab, long-term safety of intravitreal bevacizumab is still unknown . Therefore, prudent clinical judgement and caution should be exercised with the off-label use of intravitreal bevacizumab, as there have been few reports of progression of tractional retinal detachment in patients with severe proliferative diabetic retinopathy .
To summarise, the use of intravitreal bevacizumab provided a relatively clean surgical field and facilitated membrane dissection with reduced chance of iatrogenic retinal break. Therefore, bevacizumab may have potential as an adjunctive treatment to vitreoretinal surgery for the management of Eales’ disease with tractional retinal detachment. However, well-designed randomised controlled trials are essential before such a use can be unequivocally established.
- Biswas J, Sharma T, Gopal L et al (2002) Eales’ disease—an update. Surv Ophthalmol 47:197–214PubMedView ArticleGoogle Scholar
- Chanana B, Azad RV, Patwardhan S (2010) Role of intravitreal bevacizumab in the management of disease. Int Ophthalmol 30:57–61PubMedView ArticleGoogle Scholar
- Kumar A, Sinha S (2007) Rapid regression of disc and retinal neovascularization in a case of Eales’ disease after intravitreal bevacizumab. Can J Ophthalmol 42:335–336PubMedView ArticleGoogle Scholar
- Küçükerdönmez C, Akova YA, Yilmaz G (2008) Intravitreal injection of bevacizumab in Eales’ disease. Ocul Immunol Inflamm 16:63–65PubMedView ArticleGoogle Scholar
- Mansour AM, Mackensen F, Arevalo JF et al (2008) Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 146:410–416PubMedView ArticleGoogle Scholar
- Murugeswari P, Shukla D, Rajendran A et al (2008) Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and Eales’ disease. Retina 28:817–824PubMedView ArticleGoogle Scholar
- Verma A, Biswas J, Radhakrishnan S, Narayanasamy A (2010) Intra-ocular expression of vascular endothelial growth factor (VEGF) and pigment epithelial-derived factor (PEDF) in a case of Eales’ disease by immunohistochemical analysis: a case report. Int Ophthalmol 30:429–434PubMedView ArticleGoogle Scholar
- Gillies MC (2010) Bevacizumab in ophthalmology: the controversy moves forward. Clin Experiment Ophthalmol 38:333–334PubMedView ArticleGoogle Scholar
- Zhu Q, Ziemssen F, Henke-Fahle S et al (2008) Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 115:1750–1755PubMedView ArticleGoogle Scholar
- Fung AE, Rosenfeld PJ, Reichel E (2006) The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344–1349PubMedPubMed CentralView ArticleGoogle Scholar
- Arevalo JF, Maia M, Flynn HW Jr et al (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213–216PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution and reproduction in any medium, provided the original author(s) and source are credited.